Biotech’s next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja. He discusses which stocks will benefit from weight-loss drugs. He also talks about the function of Visible Alpha’s GLP-1 monitor. Tune in to find out more about the stock market today.